Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Down 76.1% in March

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the recipient of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 39,700 shares, a drop of 76.1% from the February 29th total of 166,100 shares. Based on an average trading volume of 212,600 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.2% of the shares of the stock are sold short.

Hedge Funds Weigh In On Coeptis Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of COEP. Mint Tower Capital Management B.V. bought a new position in shares of Coeptis Therapeutics during the fourth quarter valued at about $35,000. Geode Capital Management LLC bought a new position in shares of Coeptis Therapeutics during the first quarter valued at about $57,000. Morgan Stanley bought a new position in shares of Coeptis Therapeutics during the fourth quarter valued at about $64,000. Ionic Capital Management LLC bought a new position in shares of Coeptis Therapeutics during the second quarter valued at about $70,000. Finally, Shaolin Capital Management LLC bought a new position in shares of Coeptis Therapeutics during the second quarter valued at about $70,000. 13.88% of the stock is currently owned by hedge funds and other institutional investors.

Coeptis Therapeutics Stock Performance

Shares of COEP remained flat at $0.30 during trading hours on Wednesday. The stock had a trading volume of 102,358 shares, compared to its average volume of 220,260. The firm’s 50 day simple moving average is $0.48 and its 200 day simple moving average is $0.84. Coeptis Therapeutics has a 12-month low of $0.29 and a 12-month high of $2.19. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.03.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.